Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans
- 1 August 1999
- journal article
- other
- Published by Wolters Kluwer Health in Hypertension
- Vol. 34 (2) , 285-290
- https://doi.org/10.1161/01.hyp.34.2.285
Abstract
—Angiotensin-converting enzyme (ACE) inhibition significantly decreases plasminogen activator inhibitor-1 (PAI-1) without altering tissue plasminogen activator (tPA) during activation of the renin-angiotensin-aldosterone system in humans. Because ACE inhibitors and angiotensin II type 1 (AT 1 ) receptor antagonists differ in their effects on angiotensin II formation and bradykinin degradation, the present study compared the effect of equivalent hypotensive doses of an ACE inhibitor and AT 1 antagonist on fibrinolytic balance. Plasma PAI-1 antigen, tPA antigen, plasma renin activity, and aldosterone were measured in 25 normotensive subjects (19 white, 6 black; 14 men, 11 women; mean age 38.5±1.8 years; mean body mass index 25.3±0.7 kg/m 2 ) during low salt intake alone (10 mmol Na/d), low salt intake + quinapril (40 mg PO bid), and low salt intake + losartan (50 mg PO bid). Compared with low salt alone (systolic blood pressure [BP] 118.8±2.2 mm Hg), both quinapril (106.3±2.5 mm Hg, P P P =0.009), but not quinapril, lowered heart rate. Both drugs significantly lowered aldosterone ( P P P =0.03) and activity ( P =0.018). PAI-1 activity was lower during treatment with quinapril than with losartan ( P =0.015). The average PAI-1 antigen concentration was 13.0±2.0 ng/mL during low salt alone, 10.5±1.6 ng/mL during quinapril treatment, and 12.3±2.1 ng/mL during losartan treatment. In contrast, plasma tPA antigen concentrations were reduced during treatment with losartan ( P =0.03) but not with quinapril. This study provides the first evidence that ACE inhibitors and AT 1 antagonists differ in their effects on fibrinolytic balance under conditions of activation of the renin-angiotensin-aldosterone system. Further studies are needed to address the mechanism for the contrasting effects of these 2 classes of drugs on fibrinolysis and to define the clinical significance of these differences.Keywords
This publication has 35 references indexed in Scilit:
- A Comparative Study of Captopril and Enalapril on Endothelial Cell Function in Congestive Heart Failure PatientsAngiology, 1995
- Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.Journal of Clinical Investigation, 1995
- Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarctionJournal of the American College of Cardiology, 1994
- Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in cultureAtherosclerosis, 1994
- Comparison of Angiotensin-Converting Enzyme Inhibition with Angiotensin II Receptor Antagonism in the Human ForearmJournal of Cardiovascular Pharmacology, 1993
- Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.Hypertension, 1993
- Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.Hypertension, 1993
- Association of the Renin-Sodium Profile with the Risk of Myocardial Infarction in Patients with HypertensionNew England Journal of Medicine, 1991
- Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.Hypertension, 1990
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985